299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02054156 (ClinicalTrials.gov)	June 2014	1/2/2014	OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis	OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial	Cystic Fibrosis	Drug: azithromycin;Drug: placebo;Drug: Tobramycin solution for inhalation	Bonnie Ramsey	National Heart, Lung, and Blood Institute (NHLBI)	Completed	6 Months	18 Years	All	221	Phase 3	United States
2	NCT01460836 (ClinicalTrials.gov)	April 2010	25/10/2011	Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis	Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis	Cystic Fibrosis	Drug: Tobramycin solution for inhalation;Drug: Aztreonam lysine for inhalation	Novartis Pharmaceuticals	NULL	Completed	6 Years	N/A	Both		N/A	NULL
3	NCT00547053 (ClinicalTrials.gov)	December 2006	17/10/2007	Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis	A Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Amiloride Solution for Inhalation	Children's Hospital Boston	Cystic Fibrosis Foundation Therapeutics	Completed	6 Years	N/A	Both	25	Phase 1	United States
4	NCT00388505 (ClinicalTrials.gov)	February 2006	16/10/2006	Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis	A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects	Cystic Fibrosis	Drug: Tobramycin Inhalation Powder;Drug: Tobramycin Solution for Inhalation	Novartis Pharmaceuticals	NULL	Completed	6 Years	N/A	All	517	Phase 3	United States;Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom
5	NCT00097773 (ClinicalTrials.gov)	September 2004	30/11/2004	Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis	Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis	Cystic Fibrosis;Pulmonary Disease, Chronic Obstructive	Drug: Tobramycin solution for inhalation (TOBI);Drug: Oral placebo;Drug: Oral ciprofloxacin	Seattle Children's Hospital	National Heart, Lung, and Blood Institute (NHLBI);Cystic Fibrosis Foundation Therapeutics;CF Therapeutics Development Network Coordinating Center	Completed	1 Year	12 Years	All	304	Phase 2	United States
6	NCT00391976 (ClinicalTrials.gov)	November 2003	19/10/2006	Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis	The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: Tobramycin solution for inhalation 300 mg	Novartis	NULL	Completed	6 Months	N/A	All	123	Phase 3	NULL